The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 3 of the 23 sources its claims cite were checked for support.
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
Open accessAbstract
Background The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described. Methods This retrospective analysis of prospectively collected data examined patients referred to Italian Thrombosis Centers that were diagnosed with definite APS and tested positive for aPL [lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-beta2-glycoprotein I (beta2GPI) antibodies]. Laboratory data were confirmed in a central reference laboratory. Results One hundred and sixty patients were enrolled in this cohort study. The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%). The remaining four patients (2.5%) suffered from catastrophic APS. The cumulative incidence of thromboembolic events in the follow-up period was 12.2% (95% CI, 9.6-14.8) after 1 year, 26.1% (95% CI, 22.3-29.9) after 5 years and 44.2% (95% CI, 38.6-49.8) after 10 years. This was significantly higher in those patients not taking oral anticoagulants as compared with those on treatment (HR=2.4 95% CI 1.3-4.1; P<0.003). Major bleeding associated with oral anticoagulant therapy was low (0.8% patient/years). Ten patients died (seven were cardiovascular deaths). Conclusions Patients with APS and triple positivity for aPL are at high risk of developing future thromboembolic events. Recurrence remains frequent despite the use of oral anticoagulants, which significantly reduces the risk of thromboembolism.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 160 patients with definite antiphospholipid syndrome (APS) and triple positivity for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies, thromboembolic recurrence was frequent, with a cumulative incidence of 44.2% at 10 years. Oral anticoagulant treatment was associated with a significantly lower risk of recurrent thromboembolism, while major bleeding on anticoagulation was low.
Key findings
- During follow-up, 55 of 160 patients (34.4%) had a thromboembolic event (25 venous, 30 arterial); cumulative incidence was 12.2% (95% CI 9.6–14.8) at 1 year, 26.1% (95% CI 22.3–29.9) at 5 years, and 44.2% (95% CI 38.6–49.8) at 10 years.
- Oral anticoagulant status was the only predictor of thromboembolic events in multivariate Cox analysis: events occurred in 36/123 anticoagulated patients versus 19/37 non-anticoagulated patients, with HR 2.4 (95% CI 1.3–4.1; P < 0.003) for not taking oral anticoagulants; cumulative incidence was significantly higher in untreated patients (P = 0.002).
- Major bleeding was low: 8 major bleeding events, 7 in patients on oral anticoagulants (0.8% patient/years); there were 10 deaths (0.8% patients/years; 7 cardiovascular, 3 non-cardiovascular).
- Recurrence did not depend on the qualifying event: 10-year cumulative incidence was 45% for venous, 47% for arterial, and 37% for pregnancy morbidity as the qualifying event (P = ns).
Methods
- Retrospective analysis of prospectively collected data from Italian Thrombosis Centers, including 160 patients with definite APS and triple positivity for LA, aCL, and anti-β2GPI antibodies, confirmed in a central reference laboratory; inclusion required LA and anti-β2GPI positivity and aCL > 40 GPL and/or > 40 MPL units.
- Observation period from earliest diagnosis (March 1989) to March 2009; outcomes included objectively diagnosed thromboembolic events, major bleeding, and death.
- Kaplan-Meier survival analysis estimated cumulative incidence of thromboembolic events; log-rank tests compared groups; Cox regression identified predictors of the primary endpoint.
Limitations
- The paper does not include a formal limitations section; evident limitations include the observational, non-randomized treatment comparison (123 patients received long-term oral anticoagulants versus 37 who did not), so treatment effects may be confounded.
- The cohort was selected from Thrombosis Centers and restricted to triple-positive APS patients with aCL > 40 units, limiting generalizability to other APS laboratory profiles or lower-risk populations.
- Follow-up attrition was substantial: only 23 patients (14.4%) completed 10 years; pregnancy morbidity was uncommon (11 cases), and the reported percentage differs between the abstract (9.7%) and Results/Table 1 (6.9%).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Own result · 11 No full text of the sources · 6 Own interpretation · 4 Own method · 3 Sources not found · 1 Supported so far · 1 Partly supported · 1 Couldn’t confirm · 1 Not checked yet · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This selected cohort of patients differed from the large cohort described by Cervera et al. [25,26] in several aspects.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
- Supportedcites [26] source
The Patient selection section describes a multicentre cohort of 1,000 unselected patients with antiphospholipid syndrome. The citation identifies the large Cervera et al. cohort used for comparison; the assertion that the citing authors’ cohort differs is their own comparison. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As there is currently no evidence to support the superiority of oral anticoagulant therapy over antiplatelet therapy [15], antiplatelet drugs are generally recommended after an episode of stroke.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The COMMENT section reports that warfarin was not associated with fewer thrombo-occlusive events than aspirin in the studied stroke cohort. That supports the comparison, but the citing sentence generalizes it to all oral anticoagulants and antiplatelet therapies; the paper does not establish that broader claim. No page number is available in the supplied copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Less than half of the patients reported by Cervera et al. were LA positive.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
- Could not verifycites [26] sourceExperimental — accuracy not yet measured
The Laboratory studies section says LA activity was tested but gives no positivity rate. The General characteristics section says the cohort’s immunological findings were reported elsewhere. Searches for LA prevalence and a percentage below 50% found no figure in our copy (page numbers unavailable). (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The remaining four patients (2.5%) suffered from catastrophic APS.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Major bleeding associated with oral anticoagulant therapy was low (0.8% patient/years).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Our data come close to the data from Cervera et al., if we only considered primary APS patients (female/male ratio drops to 3.5:1) [25].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Our findings do not confirm the findings of previous studies [23,27] that have suggested that the recurrence of an event is more likely to occur in the same vascular district (i.e.venous or arterial).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis was VTE in 76 cases (47.5%), arterial thromboembolism in 69 cases (43.1%) and pregnancy morbidity in 11 cases (6.9%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 69- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis did not predict the type of recurrence (arterial or venous).”
- Also stated in: § Thromboembolic events during the followup period · plain
“The incidence of events during follow-up was independent of the clinical manifestations at diagnosis.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Thromboembolic events during the followup period · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative incidence of thromboembolic events in the follow-up period was 12.2% (95%CI, 9.6-14.8)after 1 year, 26.1% (95%CI, 22.3-29.9)after 5 years and 44.2% (95%CI, 38.6-49.8)after 10 years.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The quote only partly states this claim. 3
- It may state two separate claims as one. 17
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One hundred and sixty patients were enrolled in this cohort study.”
- Also stated in: § Results · plain
“Thus, 160 patients with three positive APS tests were enrolled in this cohort study.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ten patients died (seven were cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The qualifying event at diagnosis was VTE in 76 cases (47.5%), arterial thromboembolism in 69 cases (43.1%) and pregnancy morbidity in 11 cases (6.9%).”
- Also stated in: § Abstract · plain
“The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Abstract · plain
In the paper
“We had more male patients (29% vs. 18%) and primary APS cases (62% vs. 53%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of enrolled patients with obstetric complications alone was low (9.7%), highlighting that the majority of female patients with triple positivity in laboratory tests suffer from thromboembolic events [22].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were eight major bleeding events -seven in patients on oral anticoagulants (0.8% patient/years) -and 10 deaths during follow-up (0.8% patients/years; seven were cardiovascular and three were non-cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Major bleeding and death
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Fig. 2, the cumulative incidence of events after 10 years was 45%, 47% and 37% for venous, arterial and pregnancy morbidity as a qualifying event, respectively (P = ns).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Out of the 160 patients, 55 (34.4%) had a thromboembolic event during the follow-up period; 25 were VTE and 30 were arterial thromboembolism.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 189 patients considered for this study, 29 were excluded; 11 because the laboratory data were not confirmed in the reference laboratory and 18 for having both GPL and MPL aCL titers of < 40 units.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Results
plainn = 189- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequent thromboembolism occurred in 36 (16 VTE and 20 ATE) out of 123 anticoagulated patients [median International normalized ratio (INR) at the time of event 2.3], and in 19 (9 VTE and 10 ATE) out of the 37 non-anticoagulated patients.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 123- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were eight major bleeding events -seven in patients on oral anticoagulants (0.8% patient/years) -and 10 deaths during follow-up (0.8% patients/years; seven were cardiovascular and three were non-cardiovascular deaths).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Major bleeding and death
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Out of 160 patients, 123 received long-term oral anticoagulant treatment during the entire follow-up period, whereas 37 did not (13 did not take anticoagulants and 24 took aspirin alone).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One hundred and thirty-one (81.9%) patients completed the 1year follow-up, 76 (47.5%) completed 5 years and 23 (14.4%) completed 10 years of follow-up.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean follow-up was 6.0 (± 4.6) years (range 0.3-20 years).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Thromboembolic events during the followup period
plainn = 160- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Many clinical studies on APS have included patients with different laboratory profiles, and consequently, the results may lack consistency [14][15][16][17].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [14][15][16][17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As just one positive test is sufficient for APS diagnosis, there is a substantial risk of diagnosing APS in patients with either one false-positive test or with antibodies that recognize a target that is irrelevant to the syndrome.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Oral anticoagulants are recommended after a first episode of VTE [28] to prevent recurrence [29][30][31][32].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
What the sources say
- Not checked — no full text of the sourcecites [28] source
- Not matchedcites [29][30][31][32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To confirm triple positivity for aPL, and to validate the laboratory diagnosis, patient plasma from each center was also tested in a reference laboratory.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Study design and population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“However, these tests are poorly standardized, which leads to low sensitivity [2][3][4].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [2][3][4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, data were confirmed in all patients and tests were repeated in recurrent cases or each year in the majority of patients.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Both the type and site of any thromboembolic events at diagnosis were demonstrated objectively.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Data collection and clinical features at diagnosis
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recurrence remains frequent despite the use of oral anticoagulants, which significantly reduces the risk of thromboembolism.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
In the paper
“In contrast, multiple positivity shows a marked association with thromboembolic events and severe pregnancy morbidity [8][9][10][11][12][13].”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Introduction
What the sources say
- Not matchedcites [8][9][10][11][12][13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Oral anticoagulant therapy significantly reduces recurrent thromboembolism, although it might prove insufficient in some cases.”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
No prior study has described the characteristics and clinical course of APS in high-risk patients positive for all three recommended aPL tests.
“To our knowledge, no study has reported the characteristics and clinical course of a homogenous group of APS patients that are positive in all three laboratory diagnostic tests.”
“The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described.”
The paper relies on this without support.
This is the first large-scale study to examine the clinical course of a homogeneous cohort of APS patients with full positive laboratory profile.
“To our knowledge, this is the first large-scale study looking at the clinical course of a homogenous cohort of APS patients with full positive laboratory profile.”
“which to our knowledge is the first to examine patients that are positive for APS as determined by three separate tests”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite long-term anticoagulation with vitamin K antagonists, patients with thrombotic PAPS remain at substantial risk of recurrent thrombotic events, with cumulative recurrence rates approaching 20% at 5 years in observational cohorts [2].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The incidence was significantly higher in patients not taking OAs (HR 2.4, 95% CI 1.3-4.1,P < 0.003) [11].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“aPL profiling also involves consideration of antibody titers since higher titers are associated with higher risk [7,8,30,31].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients positive for the combination of LAC, antiβ 2GPI, and anti-CL antibodies,theso-called triple-positive patients, exhibit a high risk for developing a first thrombotic event and recurrence of thrombosis. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“andpatientspositiveforallthree aPLs are identified as individuals at high risk for a first clinical event and for recurrence. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [8]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“triple positivity (all 3 tests positive) is associated with thrombosis and identifies high-risk patients with aPL syndrome (APS).6,7”
From Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“At 1 year, the cumulative incidence of thromboembolic events was 12.2%, and at 10 years it was 44.2%, in a retrospective study in APS patients [11].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Of note is that many studies on triple positivity merely report patients as being positive for LA without assessing dRVVT and APTT results separately [10,[23][24][25][26][27][28][29], or even use only 1 assay [7,8,12].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The qualifying events at diagnosis were venous thromboembolism (76 cases; 47.5%), arterial thromboembolism (69 cases; 43.1%) and pregnancy morbidity (11 cases; 9.7%).”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Abstract
Reported 9.7 · recomputed 6.875
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Other | 34 (19.3) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 19.3 · recomputed 21.25
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Table 1 Demographic and clinical characteristics at diagnosis of 160 highrisk APS patients* | Characteristics | | | --- | --- | | Age years | 41.1 ± 15.0 | | Female -no. (%) | 113 (70.6) | | APS-related event at diagnosis -no. (%) | | | VTE | 76 (47.5) | | Arterial Thrombosis | 69 (43.1) | | Obstetric complications | 11 (6.9) | | Catastrophic APS | 4 (2.5) | | Autoimmune disorders -no.(%) | | | SLE | 33 (18.8) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 18.8 · recomputed 20.625
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Risk for arterial thrombosis -no. (%) | 87 (49.4) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 49.4 · recomputed 54.375
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Risk for venous thrombosisà -no. (%) | 71 (40.3) |”
§ Clinical course of high-risk patients diagnosed with antiphospholipid syndrome > Discussion
Reported 40.3 · recomputed 44.375
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M. M., Tapson, V. F., & Weg, J. G. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,035
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Asherson, R. A., Cervera, R., de Groot, P. G., Erkan, D., Boffa, M., Pietté, J. C., Khamashta, M. A., Shoenfeld, Y., & Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) · Lupus · doi:10.1191/0961203303lu394oa · Cited by 863
Cited by
Sorted by citations
Items 301–400 of 629
A review of laboratory considerations in thrombophilia testing
Ong, J., & Bennett, A. (2022) · Pathology · doi:10.1016/j.pathol.2022.09.001 · Cited by 11
Broder, A. R., Mowrey, W. B., Kim, M., Murakhovskaya, I., Billett, H. H., Neugarten, J., Costenbader, K. H., & Putterman, C. (2015) · Rheumatology · doi:10.1093/rheumatology/kev423 · Cited by 11
Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update
Kalmanti, L., & Lindhoff‐Last, E. (2020) · Hämostaseologie · doi:10.1055/s-0040-1701473 · Cited by 11
Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?
Calcaterra, I. L., Tufano, A., Lupoli, R., Iannuzzo, G., Emmi, G., & Minno, M. N. D. D. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15415 · Cited by 12
Wysokinska, E. M., & Ortel, T. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00020-0 · Cited by 11
Riancho‐Zarrabeitia, L., Martínez-Taboada, V. M., Rúa‐Figueroa, Í., Sánchez‐Alonso, F., Galindo-Izquierdo, M., Ovalles-Bonilla, J. G., Olivé, A., Vázquez, N. M., Alén, J. C., Almagro, R. M., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/9kxexc · Cited by 9
Adelhelm, J. B. H., Christensen, R., Balbi, G. G. M., & Voss, A. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-001018 · Cited by 10
“The results will be presented in national patient partner groups.”
BackgroundLambert, M., Brodovitch, A., Mège, J., Bertin, D., & Bardin, N. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103585 · Cited by 10
Antiphospholipid antibodies and thrombosis
Musiał, J. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.10.029 · Cited by 10
““double positivity” - LA+aCL IgG or LA+aβ2GPI IgG, or “triple positivity”) has usually shown marked association with the risk of thromboembolic events in the past and recurrence in the future despite the use of oral anticoagulants [21,22].”
BackgroundABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?
Nascimento, N. M., Bydlowski, S. P., Soares, R. P. S., ANDRADE, D. C. O. D., Bonfá, E., Seguro, L. P. C., & Borba, E. F. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1176-8 · Cited by 10
“Frequencies of aPL antibodies were similar among our PAPS groups and therefore the higher frequency of arterial thrombosis in O blood group cannot be explained by the previously identified aPL-mediated cell activation induced arterial events in PAPS [4, 18].”
BackgroundАйсина, Р. Б., Mukhametova, L. I., Ostryakova, E. V., et al. (2013) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750813010010 · Cited by 10
Current status and future prospects for the treatment of antiphospholipid syndrome
Marzooqi, A. A., Leone, A., Saleh, J. A., & Khamashta, M. A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1178573 · Cited by 10
Simmons, D. P., Herskovits, A. Z., Battinelli, E. M., Schur, P. H., Lemire, S. J., & Dorfman, D. M. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0790 · Cited by 11
Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome
Sirinvaravong, N., Ziccardi, M. C. R., Patnaik, S., Shah, M. K., Fernandez, G., Aliling, J.-N., & Rubin, A. (2018) · Oxford Medical Case Reports · doi:10.1093/omcr/omy024 · Cited by 10
Sciascia, S., Cecchi, I., Radin, M., Rubini, E., Suárez, A., Roccatello, D., & Rodríguez‐Carrio, J. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00211 · Cited by 10
Vardi, M., & Haran, M. Z. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04305.x · Cited by 9
Perioperative Management of Rheumatic Disease and Therapies
Zisa, D., & Goodman, S. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.09.011 · Cited by 10
Radin, M., Barinotti, A., Cecchi, I., Foddai, S. G., Rubini, E., Roccatello, D., Menegatti, E., & Sciascia, S. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208199 · Cited by 10
Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension
Zhu, R., Cheng, G.-Y., Denas, G., & Pengo, V. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.012 · Cited by 10
Self-citationAnticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.439 · Cited by 10
“1% per personyear, which is in keeping with previous studies.(30,31) This study provides additional evidence in favor of long-term anticoagulation as well as laboratory screening in patients who present with unprovoked VTE, especially if they are otherwise deemed to be at low risk of VTE recurrence and are planning to…”
ResultAnticoagulantes de acción directa en el síndrome antifosfolípido. Revisión sistemática
Girón-Ortega, J. A., & González, J. A. G. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.03.011 · Cited by 9
Risk factors and recurrent thrombosis in primary antiphospholipid syndrome
Cheldieva, F. A., Shumilova, A. A., Cherkasova, M. V., Glukhova, S. I., Lila, A. M., Nasonov, E. L., & Reshetnyak, T. M. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00114 · Cited by 9
Antiphospholipid syndrome in children
Avramovič, M. Z., & Avčin, T. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101986 · Cited by 11
“This is probably because most pathogenic aPLs are of the IgG2 subclass [23,24].”
Devreese, K. M. J. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1791699 · Cited by 13
“13 Therefore,it is important to test for the three groups of aPL (LA, aCL, and a β 2GPI) in patients with thrombosis who may be associated with APS.”
Peleg, H., Naparstek, Y., Regola, F., Tincani, A., Pengo, V., & Denas, G. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102408 · Cited by 10
Self-citationPontara, E., Cattini, M. G., Bison, E., Cheng, C., Denas, G., & Pengo, V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.004 · Cited by 9
Self-citationGullapalli, K., Prasad, R. M., Al-Abcha, A. K., et al. (2022) · Cureus · doi:10.7759/cureus.29449 · Cited by 9
“Patients who exhibit positive testing for all three antibodies (triple-positivity) appear to have a worse prognosis due to their high risk for recurrent thrombosis and pregnancy complications [1,2].”
BackgroundImpact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients
Kansuttiviwat, C., Niprapan, P., Tantiworawit, A., Norasetthada, L., Rattarittamrong, E., Rattanathammethee, T., Hantrakool, S., Piriyakhuntorn, P., Punnachet, T., Hantrakun, N., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279450 · Cited by 9
Interpretation of laboratory data and need for reference laboratories
Pengo, V., Denas, G., Banzato, A., Bison, E., Bracco, A., Visentin, M. S., Hoxha, A., & Ruffatti, A. (2012) · Lupus · doi:10.1177/0961203312437271 · Cited by 9
Self-citationCan hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Devaux, C. A., Camoin‐Jau, L., Mège, J., & Raoult, D. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.12.010 · Cited by 9
“In antiphospholipid syndrome (APS) an important risk of thrombosis relapse should be considered.(94) HCQ benefit to protect against thromboembolism was described more than 30-years ago, with reported reduction of erythrocyte aggregation in vitro and”
Buchholz, I., McDonnell, T. C. R., Nestler, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84021-2 · Cited by 9
Anderson, M., & Belmont, M. H. (2022) · Lupus · doi:10.1177/09612033221074920 · Cited by 9
Perioperative Management of Rheumatic Disease and Therapies
Zisa, D., & Goodman, S. M. (2022) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2022.02.005 · Cited by 9
Ocular findings in asymptomatic patients with primary antiphospholipid syndrome
Neto, T. D. S. R., Neto, E. D., Balbi, G. G. M., et al. (2022) · Lupus · doi:10.1177/09612033221133687 · Cited by 9
“In contrast, triple positivity was not associated with PAMM in spite of previous observation that this profile imposes the greatest risk for thrombotic and obstetric events.(29) Macular drusen-like deposit was diagnosed in one patient, a condition usually related to aging(30) but the patient was 41 years old.”
ResultTask Force Report on Antiphospholipid Syndrome Clinical Research
Erkan, D., Pierangeli, S. S., & Lockshin, M. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_17 · Cited by 9
TRIPODI, A., MOIA, M., & PENGO, V. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04284.x · Cited by 9
Self-citationLaboratory tests in rheumatology: A rational approach
Suresh, E. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18076 · Cited by 9
“33 The association with thrombosis is stronger for lupus anticoagulant than with the other 2 antibodies, with different studies 34 fi nding an odds ratio ranging from 5 to 16.”
BackgroundThe Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies
Grosso, G., Sandholm, K., Antovič, A., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1347-5655 · Cited by 8
He, L., & Sims, C. A. (2024) · Seminars in Reproductive Medicine · doi:10.1055/s-0044-1790225 · Cited by 9
“61 The increased risk of thrombosis in normal pregnancy is heightened in APS pregnancies: despite treatment, about 1 in 10 to 1 in 50 APS pregnancies are complicated by thrombosis.”
Characterization of recurrent thrombosis in pediatric antiphospholipid syndrome
Avila, L., Amiri, N., Zavareh, Z. T., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26565 · Cited by 8
“We should note that our estimates, with wider CI, are less precise than those reported by Pengo et al.(7) The adjusted model included age at the time of the index thrombotic event and sex.”
ResultInfluentialAssessing disease activity and damage in antiphospholipid syndrome
ANDRADE, D. C. O. D., & Tektonidou, M. G. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109727 · Cited by 8
Qushmaq, N. A., & Al-Emadi, S. A. (2014) · ISRN Rheumatology · doi:10.1155/2014/348726 · Cited by 8
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders
Valanejad, S. M., & Davis, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020968551 · Cited by 8
Antiphospholipid Syndrome in Patients with Venous Thromboembolism
Pengo, V., & Denas, G. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1749590 · Cited by 8
“17 When type and con fi rmation of positive aPL were considered, having the same type of aPL on two occasions or having more than one type of aPL on the same or different occasions is associated with recurrent thrombosis in patients with a fi rst unprovoked VTE who stop anticoagulant therapy in…”
BackgroundSelf-citationDevreese, K. M. J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3175-1_20 · Cited by 8
Identification of the binding site for fondaparinux on Beta2-glycoprotein I
Kolyada, A. Y., Biasio, A. D., & Beglova, N. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.06.009 · Cited by 8
“Antiphospholipid antibodies directed to beta2-glycoprotein I (β2GPI) associate the most with thrombotic events in APS patients [2,3].”
BackgroundIoannou, Y. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker353 · Cited by 8
Radin, M., Foddai, S. G., Cecchi, I., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.03.019 · Cited by 8
Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances
Undas, A., Musiał, J., & Ząbczyk, M. (2025) · Rheumatology International · doi:10.1007/s00296-025-06050-8 · Cited by 8
“MI is observed in ~ 2–5.5% of patients with APS [1, 11, 41–44], and often presents as the first manifestation of the disease (73”
InfluentialYoshinaga, K., Otsuka, Y., Furukawa, T., et al. (2021) · JA Clinical Reports · doi:10.1186/s40981-021-00427-x · Cited by 7
“are “triple-positive” (positive lupus anticoagulant, anticardiolipin, and anti-β2GPI antibodies) [11].”
Zhou, Y., Hu, C., Qi, W., Long, Y., Huang, C. L., Wang, Q., Tian, X., Zhao, J., Li, M., & Zeng, X. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000924 · Cited by 7
Yelnik, C., Erton, Z. B., Drumez, É., et al. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152347 · Cited by 7
Self-citationForet, T., Dufrost, V., Lagrange, J., et al. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01140-1 · Cited by 7
“However, in patients considered at high risk of thrombosis especially with triple positivity (LA positivity + aCL positivity IgG or IgM + aβ2-GPI positivity IgG or IgM) [25, 26], some studies showed a decrease in ETP and thrombin peak [27–29].”
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies
Radin, M., Barinotti, A., Foddai, S. G., Cecchi, I., Rubini, E., Roccatello, D., Menegatti, E., & Sciascia, S. (2021) · Immunologic Research · doi:10.1007/s12026-021-09208-1 · Cited by 7
Marco, A., & Marco, P. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1767728 · Cited by 7
Hoxha, A., Perin, N., Lovisotto, M., Calligaro, A., Ross, T. D., Favarò, M., Tonello, M., Doria, A., & Simioni, P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103180 · Cited by 7
Postoperative Risk of Venous Thromboembolism in Rheumatic Disease Patients
Wong, L. E., & Bass, A. R. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-014-0488-6 · Cited by 7
Antiphospholipid syndrome: Unusual clinical presentations
Greaves, M. (2011) · Thrombosis Research · doi:10.1016/s0049-3848(11)70013-5 · Cited by 7
“Evidence from extensive case series indicates there is significant morbidity and mortality from thrombosis in unequivocal APS despite antithrombotic therapy; iatrogenic bleeding is frequent, also [23,29].”
BackgroundCostedoat-Chalumeau, N., Saadoun, D., & Pietté, J. C. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.01.010 · Cited by 7
Khodashahi, M., REZAIEYAZDI, Z., & SAHEBARI, M. (2020) · Archives of Rheumatology · doi:10.5606/archrheumatol.2020.7375 · Cited by 8
Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome
Riva, N., & Gatt, A. (2019) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10314116 · Cited by 7
Breen, K. A. (2017) · Wiley eBooks · doi:10.1002/9781119095606.ch8 · Cited by 7
Ibrahim, A. A., Shadi, H. W. E., Elamin, A. A. Y., & Draz, H. E. (2023) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-023-00175-z · Cited by 7
Antiphospholipid Syndrome and Kidney Involvement
Simone, E. D., Sciascia, S., Fenoglio, R., Oddone, V., Barreca, A., & Roccatello, D. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000529229 · Cited by 11
“There is sound evidence that patients with more than one positive test, and particularly those who are triple-positive for LA, aCL, and a β 2GP-1 (either IgG or IgM), show the strongest association with APS [44, 45].”
BackgroundMittal, P., Pacheco, M., Trives-Folguera, L., et al. (2024) · Lupus · doi:10.1177/09612033241266989 · Cited by 6
“15 However, a prospective cohort study in SLE patients reported that LAwas most predictive of thrombosis risk, and that addition of aCL and/or a β 2GP1 did not augment risk.”
Rivaroxaban to treat thrombotic antiphospholipid syndrome
Urbanus, R. T. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30107-7 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Zhang, Y., Lin, M., Hao, X., et al. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00720-0 · Cited by 6
“What’s more, evidence shows that patients with more than one positive test, and particularly those with all three positive aPL tests (referred to as triple positive), are those with a strong association with clinical events [25].”
BackgroundBucci, T., Ames, P. R. J., Cammisotto, V., Bartimoccia, S., Triggiani, M., Parente, R., Ciampa, A., Pignatelli, P., Carnevale, R., & Pastori, D. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102832 · Cited by 6
Assessment of antiphospholipid antibodies profiles based on severity of COVID-19 pneumonia
Bnina, A. B., Dhia, R. B., Gnaba, S., et al. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.42.110.33020 · Cited by 6
“On the other hand, combined positivity of LAC, ACL, and anti-β2GPI (triple positive APL) and high titers of these antibodies have been shown to be high risk factors of thrombotic events [21-24].”
BackgroundBarilaro, G., Rocca, C. D., Esteves, A., Cervera, R., & Espinosa, G. (2022) · Rheumatology · doi:10.1093/rheumatology/keac619 · Cited by 6
Moore, G. W., Foxton, E., Platton, S., Yartey, N., White, D., & MacDonald, S. G. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.08.009 · Cited by 6
Forecasting the Future of Antiphospholipid Syndrome: Prospects and Challenges.
Taylor, A., Kumar, S., & Pozzi, N. (2023) · PubMed Central · Cited by 6
Antithrombotic treatment for stroke associated with antiphospholipid antibodies
Arachchillage, D. J., Machin, S. J., & Cohen, H. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.892413 · Cited by 6
“, with LA, aCL and ab2-GPI) on standard intensity anticoagulation showing a 30% recurrence rate over a 6-year follow-up period [4].”
MethodZamora-Medina, M. D. C., Hinojosa‐Azaola, A., Núñez‐Álvarez, C. A., Vargas-Ruíz, Á. G., & Romero‐Díaz, J. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4381-y · Cited by 8
Navas, M. A. M., Saldarriaga, C., Aguilar, C., Builes-Montaño, C. E., Echeverri, A. Q., Aristizábal, N., Tobón, J. J. Z., Vargas, F., Zapata, A. L., Felipe, Ó., et al. (2012) · Revista Colombiana de Reumatología · doi:10.1016/s0121-8123(12)70016-6 · Cited by 8
Diagnostik der venösen Thrombose und Lungenembolie
SCHELLONG, S. M. (2010) · Der Internist · doi:10.1007/s00108-009-2513-9 · Cited by 6
Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review)
Gavris, C. M., Nedelcu, L. D., & Pascu, A. M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9718 · Cited by 5
Analytical dilemmas in lupus anticoagulant detection
Moore, G. W. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00104 · Cited by 5
Yelnik, C., Bauters, A., Labreuche, J., Desvages, M., Launay, D., HACHULLA, E., Dubucquoi, S., Lancel, S., Frimat, M., & Lambert, M. (2025) · RMD Open · doi:10.1136/rmdopen-2025-005489 · Cited by 5
Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting
Ducker, C. B., Preece, M. V., Pericleous, C., et al. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101364 · Cited by 5
Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome
Efthymiou, M., Bertolaccini, M. L., & Cohen, H. (2024) · Rheumatology · doi:10.1093/rheumatology/kead623 · Cited by 5
Žigon, P., Boštic, N., Ambrožič, A., Rotar, Ž., Blokar, E., Ogrič, M., & Čučnik, S. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0570 · Cited by 5
Use of direct oral anticoagulants in antiphospholipid syndrome: Reply
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14674 · Cited by 5
Sciascia, S., Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Vaccarino, A., Rossi, D., & Roccatello, D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.621590 · Cited by 5
“The clinical course in persons with high-risk aPL profiles (triple positive patients) has been well-described (8); the role of extracriteria aPL, with or without concomitant positive LA, and their clinical impact on positive subjects has been the subject of debate over the last decades, with heterogeneous conclusions…”
BackgroundDelarue, A., Dragon‐Durey, M., & Darnige, L. (2022) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2022.04.031 · Cited by 5
Cheng, C., Bison, E., Pontara, E., et al. (2022) · Lupus · doi:10.1177/09612033221118465 · Cited by 5
Self-citationThe use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome
Sayar, Z., Burke, S., Mittal, P., & Cohen, H. (2022) · Lupus · doi:10.1177/09612033221122147 · Cited by 5
“Annualised recurrent thrombosis rates in patients with APS on vitamin K antagonist (VKA) were 1 3–4 0% in two prospective randomised controlled trials(3,4) and 4 3% and 4 8% in a prospective(5) and retrospective cohort study, respectively, the latter in triple aPL-positive patients.(2) In a systematic review of 728 pa…”
BackgroundInfluentialNoble, H., Crossette‐Thambiah, C., Odho, Z., et al. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1757633 · Cited by 5
Ganapati, A., Mathew, J., Yadav, B., et al. (2022) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-022-01611-4 · Cited by 5
“Despite adherence to OAC, a 29% cumulative incidence of subsequent thromboembolic events has been reported among APS patients [3].”
BackgroundNeto, E. D. D. S., Neto, T. R., Signorelli, F., et al. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06613-9 · Cited by 5
“demonstrated that patients with triple positivity to aPL are at higher risk of re-thrombosis if not adequately anticoagulated [43].”
BackgroundRisks Following Total Knee Arthroplasty in Patients Who Have Antiphospholipid Syndrome
Zhang, Z., Chi, J. A., Duensing, I. M., et al. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.11.037 · Cited by 5
Matta, B. N., Uthman, I. W., Taher, A. T., & Khamashta, M. A. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.811183 · Cited by 5
Laboratory Approach to Thrombotic Risk
Marlar, R. A., Fink, L. M., & Miller, J. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00041-5 · Cited by 5
Nojima, J., Motoki, Y., Hara, K., Sakata, T., & Ichihara, K. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000599 · Cited by 5
Belančić, A., Vranić, L., Ševeljević, I., et al. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.020 · Cited by 5
Direct-acting oral anticoagulants in antiphospholipid syndrome
Reshetnyak, T. M., & Nurbaeva, K. S. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-708-715 · Cited by 5
Coexistent antiphospholipid syndrome and myeloproliferative neoplasm
Sayar, Z., Nallamilli, S., Efthymiou, M., Lambert, J., & Cohen, H. (2021) · Lupus · doi:10.1177/09612033211021154 · Cited by 5
“8% in a retrospective cohort study of triple aPLpositive APS patients (11).”
BackgroundMartins, F., & Campos, T. M. L. (2021) · TH Open · doi:10.1055/s-0041-1736289 · Cited by 6
Bradáčová, P., Slavík, L., Skoumalová, A., Úlehlová, J., Kriegová, E., Manukyan, G. P., Friedecký, D., Piskláková, B., Ullrychová, J., Procházková, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168973 · Cited by 5
“0% of patients) is consistent with the clinically increased incidence of thromboses in triple-positive patients when all three aPL (LA, aCL, and anti-β2GPI) are present simultaneously [10,12], but not statistically significant.”
Result
Metadata
- Authors
- PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., BANZATO, A., PADAYATTIL JOSE, S., & ILICETO, S.
- Affiliations
- University of Padua (IT)
- University of Bologna (IT)
- University of Perugia (IT)
- University of Cagliari (IT)
- Corresponding author
- PENGO, V.
- ORCID
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 8
- Issue
- 2
- Pages
- 237-242
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2119266650
- Cited by
- 632
- References
- 39
- Citations by year
- 2026: 37 · 2025: 31 · 2024: 40 · 2023: 47 · 2022: 52 · 2021: 45 · 2020: 55 · 2019: 50 · 2018: 41 · 2017: 33 · 2016: 38 · 2015: 35 · 2014: 32 · 2013: 30 · 2012: 30
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- antiphospholipid syndrome, triple positivity, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, venous thromboembolism, arterial thromboembolism, pregnancy morbidity, catastrophic antiphospholipid syndrome, oral anticoagulation, thromboembolic recurrence, major bleeding, cardiovascular mortality
- MeSH terms
- Administration, Oral, Adult, Aged, Anticoagulants, Catastrophic Illness, Female, Hemorrhage, Humans, Italy, Male, Middle Aged, Predictive Value of Tests, Pregnancy, Pregnancy Complications, Cardiovascular, Recurrence, Retrospective Studies, Risk Factors, Time Factors, Biomarkers, Incidence, Proportional Hazards Models, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Treatment Outcome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin, Disease Progression, Risk Assessment, Kaplan-Meier Estimate, beta 2-Glycoprotein I, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
